Page last updated: 2024-11-05

chelidamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID8743
CHEMBL ID252909
SCHEMBL ID742928
MeSH IDM0125308

Synonyms (75)

Synonym
chelidamic acid
nsc-3983
2, 1,4-dihydro-4-oxo-
138-60-3
nsc3983
smr000036248
EU-0100298
lopac-c-8011
NCGC00015270-01
4-oxo-1h-pyridine-2,6-dicarboxylic acid
2,6-pyridinedicarboxylic acid, 1,4-dihydro-4-oxo-
LOPAC0_000298
MLS000042771
NCGC00093748-02
NCGC00093748-01
NCGC00015270-02
C 8011 ,
bdbm50229870
4-oxo-1,4-dihydropyridine-2,6-dicarboxylic acid
C0821
4-hydroxypyridine-2,6-dicarboxylic acid
NCGC00015270-04
CHEMBL252909 ,
AKOS000279986
499-51-4
AC-907/25014159
4-oxo-1,4-dihydro-2,6-pyridinedicarboxylic acid
AKOS003233475
A18191
HMS3260L18
einecs 205-335-8
unii-1a59bh8sxe
1,4-dihydro-4-oxopyridine-2,6-dicarboxylic acid
1a59bh8sxe ,
nsc 3983
A827903
STL259705
CCG-204393
STK793046
HMS2439A21
NCGC00015270-03
BP-12395
chelidamic acid hydrate
FT-0623584
LP00298
SCHEMBL742928
BBL028110
NCGC00260983-01
tox21_500298
4-oxo-1,4-dihydro-2,6-pyridinedicarboxylic acid #
XTLJJHGQACAZMS-UHFFFAOYSA-N
J-400830
chelidamic acid (4-hydroxypyridine-2,6-dicarboxylic acid)
4-hydroxy-2,6-pyridinedicarboxylic acid
DS-1684
2,6-pyridinedicarboxylic acid, 4-hydroxy-
CS-W017065
HY-W016349
DTXSID00160451
J-515530
1,4-dihydro-4-oxo-2,6-pyridinedicarboxylic acid
mfcd00066478
chelidamic acid, aldrichcpr
sr-01000075782
SR-01000075782-1
FT-0712040
Q2667856
AMY13329
SDCCGSBI-0050286.P002
NCGC00015270-05
SY246016
4-hydroxypyridine-2,6-dicarboxylicacid
CS-0166907
EN300-95632
Z2900188067
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency17.74070.140911.194039.8107AID2451
thioredoxin reductaseRattus norvegicus (Norway rat)Potency51.77400.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
NFKB1 protein, partialHomo sapiens (human)Potency3.54810.02827.055915.8489AID895; AID928
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency0.42280.707912.194339.8107AID720542
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.85290.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00220.540617.639296.1227AID2364; AID2528
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency11.22020.050127.073689.1251AID588590
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
M-phase phosphoprotein 8Homo sapiens (human)Potency0.79430.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.03160.00106.000935.4813AID943
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency10.69100.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
glyoxylate catabolic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
4-hydroxyproline catabolic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
oxalate metabolic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
pyruvate biosynthetic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
glyoxylate metabolic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
N-acetylneuraminate catabolic process4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein binding4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
4-hydroxy-2-oxoglutarate aldolase activity4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
protein homodimerization activity4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
(4S)-4-hydroxy-2-oxoglutarate aldolase activity4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
N-acetylneuraminate lyase activity4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
mitochondrion4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
mitochondrial matrix4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
mitochondrion4-hydroxy-2-oxoglutarate aldolase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID321444Inhibition of Escherichia coli NAL at 20 mM2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID321446Antibacterial activity against Escherichia coli at 20 uM relative to control2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID313850Inhibition of dihydrodipicolinate synthase2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Conformationally constrained diketopimelic acid analogues as inhibitors of dihydrodipicolinate synthase.
AID321440Inhibition of Escherichia coli DHDPS at 20 mM2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID321442Inhibition of Mycobacterium tuberculosis DHDPS at 20 mM2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID321441Inhibition of Bacillus anthracis DHDPS at 20 mM2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID321443Inhibition of methicillin-resistant Staphylococcus aureus DHDPS at 20 mM2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibiting dihydrodipicolinate synthase across species: towards specificity for pathogens?
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.85)18.7374
1990's1 (3.85)18.2507
2000's7 (26.92)29.6817
2010's11 (42.31)24.3611
2020's6 (23.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.22 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index5.46 (4.65)
Search Engine Demand Index35.06 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]